Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on July 31, 2025, to announce its financial results for the second quarter ended June 30, 2025. The report primarily includes a press release detailing these results. While the specific financial figures are not detailed within the 8-K text itself, investors should refer to the furnished press release (Exhibit 99.1) for comprehensive information regarding the company's performance, revenue, profitability, and any forward-looking guidance provided for the remainder of the fiscal year. This filing serves as the official notification of the company's quarterly performance. Investors are encouraged to review the press release to understand key operational updates, product pipeline progress, and any strategic developments that may have influenced the financial outcomes. The information provided in this 8-K, specifically the financial results, is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal implications as formally filed information.
Key Highlights
- 1Alnylam Pharmaceuticals (ALNY) announced Q2 2025 financial results via an 8-K filing on July 31, 2025.
- 2The filing includes a press release (Exhibit 99.1) containing the detailed financial results for the quarter ended June 30, 2025.
- 3Investors must consult Exhibit 99.1 for specific financial performance data, including revenue and earnings.
- 4The information regarding financial results is furnished and not considered 'filed' for legal purposes under Section 18 of the Exchange Act.
- 5The 8-K also includes the Cover Page Interactive Data File as Exhibit 104.